Hostname: page-component-745bb68f8f-l4dxg Total loading time: 0 Render date: 2025-02-06T09:37:06.615Z Has data issue: false hasContentIssue false

Transient left bundle branch block and left ventricular dysfunction in a patient with NLRP1-associated autoinflammation with arthritis and dyskeratosis syndrome

Published online by Cambridge University Press:  25 January 2019

Mark R. Garrelfs*
Affiliation:
Department of Pediatric Cardiology, Radboud University Medical Centre, Nijmegen, The Netherlands
Esther Hoppenreijs
Affiliation:
Department of Pediatric Rheumatology, Radboud University Medical Centre, Nijmegen, The Netherlands
Ronald B. Tanke
Affiliation:
Department of Pediatric Cardiology, Radboud University Medical Centre, Nijmegen, The Netherlands
*
Author for correspondence: Garrelfs MR, Department of Pediatric Cardiology, Radboud University Medical Centre, Nijmegen, The Netherlands. E-mail: Mark.garrelfs@radboudumc.nl
Rights & Permissions [Opens in a new window]

Abstract

The NLRP1-associated autoinflammation with arthritis and dyskeratosis syndrome is a rare novel autoinflammatory disorder. Cardiac involvement has not been previously reported. We present a 12-year-old girl with NLRP1-associated autoinflammation with arthritis and dyskeratosis syndrome who was diagnosed with severely impaired left ventricular function and complete left bundle branch block during an exacerbation of the disease. Cardiac dysfunction proved to be rapidly reversible after initiation of high-dose methylprednisolone.

Type
Brief Report
Copyright
© Cambridge University Press 2019 

The NLRP1-associated autoinflammation with arthritis and dyskeratosis syndrome is a novel autoinflammatory disorder characterised by dyskeratosis, arthritis, recurrent fever, and elevated acute phase reactants.Reference Grandemange, Sanchez and Louis-Plence 1 Till date, only three patients have been described in the literature. Cardiac involvement has not been previously reported. We present a 12-year-old girl with NLRP1-associated autoinflammation with arthritis and dyskeratosis syndrome, who was diagnosed with severely impaired left ventricular function and complete left bundle branch block during an exacerbation of the disease. This proved to be rapidly reversible after initiation of high-dose methylprednisolone.

Case report

We report the case of a 12-year-old girl with NLRP1-associated autoinflammation with arthritis and dyskeratosis syndrome, who was seen at the emergency department with headache, abdominal pain, vomiting, diarrhoea, malaise, and fluctuating fever. There was no history of recent infections. Her history revealed a splenectomy years before and an ongoing tubulo-interstitial nephritis. At that time, the patient was treated with amlodipine 2.5 mg twice daily, leflunomide 10 mg once daily, prednisone 3.5 mg once daily, which was being tapered since July 2017, and canakinumab 150 mg once every 4 weeks. The patient was considered immunocompromised due to her medication and a chronic T-lymphocytopenia.

Physical examination showed a pale, tachypnoeic child with a normal oxygen saturation while breathing ambient air. She had a tachycardia of 135 beats per minute and a blood pressure of 98/73 mmHg. Auscultation of the lungs, heart, and abdomen revealed no abnormalities. Her abdomen was diffusely painful on palpation and the liver was palpable 1 cm below the ribs. Her temperature was 36.6°C. Besides the known dyskeratosis, there were no other skin lesions.

Laboratory studies (Table 1) revealed elevated acute phase reactants, including ferritin elevation of liver enzymes and creatinine. She was hyponatraemic, hyperkalaemic, and hypomagnesiemic. Blood gas evaluation showed a metabolic acidosis, with elevated lactate levels. An elevated creatine kinase was noted but other cardiac biomarkers were not tested. Cytokine profiling revealed elevated IL-6, IL-10, and IL-18.

Table 1 Laboratory results.

IFN-g=interferon gamma; MIG=monokine induced by interferon gamma; sIL2R=soluble interleukin 2 receptor

A chest X-ray showed no abnormalities. Her ECG revealed a complete left bundle branch block (Fig 1a). Echocardiography showed a decreased left ventricular function, with a shortening fraction of 16.7% – reference value >26% – and ejection fraction of 34.8% – reference range 56–78% (Fig 2a; Supplementary Video 1).Reference Tissot, Singh and Sekarski 2

Figure 1 (a) ECG made at presentation, before treatment with intravenous methylprednisolone, showing complete left bundle branch block. (b) ECG made on day 1, 24 hours after initiation of treatment with intravenous methylprednisolone, showing no signs of a left bundle branch block.

Figure 2 Echocardiography findings. (a) M-mode echocardiographic assessment at presentation (day 0). (b) M-mode echocardiographic assessment after 24 hours of intravenous methylprednisolone (day 1). (c) M-mode echocardiographic assessment after 72 hours of intravenous methylprednisolone (day 3).

Suspecting a viral infection with a secondary severe exacerbation of her autoinflammatory disorder complicated by multi-organ failure, the patient was started on high-dose methylprednisolone (30 mg/kg/day) after a fluid challenge with isotonic saline. Because a bacterial infection could not be ruled out at the time, she was started on intravenous ceftriaxone.

Within 24 hours after initiation of therapy, the patient felt markedly better and we repeated our cardiologic evaluation. Strikingly, repeat ECG showed no signs of a conduction disturbance (Fig 1b) and echocardiography revealed a normalised left ventricular function with a shortening fraction of 34.7% and an ejection fraction of 63.6% (Fig 2b; Supplementary Video 2). Two days later, further improvement of cardiac function with a shortening fraction of 41.2% and an ejection fraction of 72.2% was noted (Fig 2c; Supplementary Video 3). At this point, her electrolytes had not been corrected (Table 1).

Blood cultures remained negative and thus antibiotics were ceased after 48 hours. There was a marked improvement of liver function tests but due to persistent oliguria the patient was started on chronic venovenous haemodialysis. Because of clinical improvement, the patient could be discharged from the paediatric intensive care unit to the ward where cardiac function remained unremarkable.

Discussion

Cardiac involvement in autoimmune or autoinflammatory disorders can manifest as pericarditis, myocarditis, endocarditis, and coronary artery disease.Reference Comarmond and Cacoub 3 The NLRP1-associated autoinflammation with arthritis and dyskeratosis syndrome is a rare autoinflammatory disorder, characterised by diffuse skin dyskeratosis, arthritis, and recurrent fever. This girl has a de novo heterozygous mutation (c.3641C>G, p.Pro1214Arg) in the NLRP1 gene (1). Before this report, cardiac involvement had not been reported in patients with NLRP1-associated autoinflammation with arthritis and dyskeratosis syndrome.

We described a patient that developed left ventricular dysfunction and conduction disturbance during an exacerbation of her autoinflammatory disease. A striking finding was the rapid resolution of these abnormalities after initiation of high-dose intravenous methylprednisolone.

We postulate that the observed exacerbation of our patients disease resulted in massive release of inflammatory mediators which caused myocardial depression and conduction disturbances, similar to those seen in patients with septicemia.Reference Rich, McGarvey and Teener 4 , Reference Mann 5 Primary myocarditis seems less likely due to the striking improvement shortly after initiating immunosuppressive therapy, but cannot be ruled out completely.

Cytokines function as mediators of immune and inflammatory reactions. They are thought to play a crucial role in the early decrease in cardiomyocyte contractility during sepsis.Reference Sergi, Shen and Lim 6 Increased circulating and intracardial cytokines are furthermore associated with chronic heart failure, ischemic myocardial dysfunction, coronary artery disease, left ventricular remodelling, and dysfunction and development of a dilated cardiomyopathy.Reference Mann 5 , Reference Novick, Kim and Kaplanski 7 Reference Hedayat, Mahmoudi and Rose 10

Indeed, several interleukins, including IL-6 and IL-18, were elevated during this exacerbation in our autoinflammatory disorder patients.

The observed co-occurrence of electrolyte disturbances could have exacerbated the cardiac abnormalities. However, we believe this only played a minor role as cardiac function improved promptly after initiation of immunosuppressive therapy, despite persisting electrolyte disturbances (Table 1).

Conclusion

Acute cardiac dysfunction and conduction disturbances can be seen in patients with NLRP1-associated autoinflammation with arthritis and dyskeratosis syndrome. Increased circulating cytokines most likely play a crucial role in the development of the described cardiac abnormalities, although the exact pathophysiologic mechanism remains unclear.

Acknowledgements

The authors thank Ellen J.H. Schatorjé for her review of our manuscript.

Financial support

This research received no specific grant from any funding agency, or from commercial or not-for-profit sectors.

Conflicts of interest

None.

Ethical standards

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants, or their parents, included in the study. Additional informed consent was obtained from all individual participants, or their parents, for whom identifying information is included in this article.

Footnotes

Cite this article: Garrelfs MR, Hoppenreijs E, Tanke RB. (2019) Transient left bundle branch block and left ventricular dysfunction in a patient with NLRP1-associated autoinflammation with arthritis and dyskeratosis syndrome. Cardiology in the Young29: 435–438. doi: 10.1017/S1047951118002342

References

1. Grandemange, S, Sanchez, E, Louis-Plence, P, et al. A new autoinflammatory and autoimmune syndrome associated with NLRP1 mutations: NAIAD (NLRP1-associated autoinflammation with arthritis and dyskeratosis). Ann Rheum Dis 2017; 76: 11911198.10.1136/annrheumdis-2016-210021Google Scholar
2. Tissot, C, Singh, Y, Sekarski, N. Echocardiographic evaluation of ventricular function—for the neonatologist and pediatric intensivist. Front Pediatr 2018; 6: 79.Google Scholar
3. Comarmond, C, Cacoub, P. Myocarditis in auto-immune or auto-inflammatory diseases. Autoimmun Rev 2017; 16: 811816.Google Scholar
4. Rich, MM, McGarvey, ML, Teener, JW, et al. ECG changes during septic shock. Cardiology 2002; 97: 187196.Google Scholar
5. Mann, DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res 2015; 116: 12541268.10.1161/CIRCRESAHA.116.302317Google Scholar
6. Sergi, C, Shen, F, Lim, DW, et al. Cardiovascular dysfunction in sepsis at the dawn of emerging mediators. Biomed Pharmacother 2017; 95: 153160.Google Scholar
7. Novick, D, Kim, S, Kaplanski, G, et al. Interleukin-18, more than a Th1 cytokine. Semin Immunol 2013; 25: 439448.Google Scholar
8. Raeburn, CD, Dinarello, CA, Zimmerman, MA, et al. Neutralization of IL-18 attenuates lipopolysaccharide-induced myocardial dysfunction. Am J Physiol Heart Circ Physiol 2002, pp 650657.Google Scholar
9. Pomerantz, BJ1, Reznikov, LL, Harken, AH, et al. Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proc Natl Acad Sci USA 2001; 98: 28712876.Google Scholar
10. Hedayat, M1, Mahmoudi, MJ, Rose, NR, et al. Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail Rev 2010; 15: 543562.Google Scholar
Figure 0

Table 1 Laboratory results.

Figure 1

Figure 1 (a) ECG made at presentation, before treatment with intravenous methylprednisolone, showing complete left bundle branch block. (b) ECG made on day 1, 24 hours after initiation of treatment with intravenous methylprednisolone, showing no signs of a left bundle branch block.

Figure 2

Figure 2 Echocardiography findings. (a) M-mode echocardiographic assessment at presentation (day 0). (b) M-mode echocardiographic assessment after 24 hours of intravenous methylprednisolone (day 1). (c) M-mode echocardiographic assessment after 72 hours of intravenous methylprednisolone (day 3).

Garrelfs et al. supplementary material

Garrelfs et al. supplementary material 1

Download Garrelfs et al. supplementary material(Video)
Video 338.4 KB

Garrelfs et al. supplementary material

Garrelfs et al. supplementary material 2

Download Garrelfs et al. supplementary material(Video)
Video 705.9 KB

Garrelfs et al. supplementary material

Garrelfs et al. supplementary material 3

Download Garrelfs et al. supplementary material(Video)
Video 725.9 KB
Supplementary material: File

Garrelfs et al. supplementary material

Garrelfs et al. supplementary material 4

Download Garrelfs et al. supplementary material(File)
File 10.5 KB